News Features Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends Michael O'Riordan January 06, 2023
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Features FFR’s Future: Negative Trials Spur Debate Over Technology’s Role Michael O'Riordan December 23, 2021
News Features Roughly 80% of ESC Guideline Writers Have Financial COIs Michael O'Riordan April 01, 2021
News Features Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI? Michael O'Riordan December 02, 2020
News Features Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate Michael O'Riordan November 27, 2017